The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Global variation in copy number in the human genome
Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., Fiegler, H., Shapero, M. H., Carson, A. R., Chen, W., et al. (2006) · Nature · doi:10.1038/nature05329 · Cited by 4,288
Epigenetic differences arise during the lifetime of monozygotic twins
Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., Heine-Suñer, D., Cigudosa, J. C., Urioste, M., Benitez, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500398102 · Cited by 3,602
Nan, X., Ng, H.-H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., & Bird, A. (1998) · Nature · doi:10.1038/30764 · Cited by 3,440
CpG Islands in vertebrate genomes
Gardiner-Garden, M., & Frommer, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90689-9 · Cited by 3,353
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
The Role of DNA Methylation in Mammalian Epigenetics
Jones, P. A., & Takai, D. (2001) · Science · doi:10.1126/science.1063852 · Cited by 2,070
The DNA methyltransferases of mammals
Bestor, T. H. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.16.2395 · Cited by 2,041
Relative Impact of Nucleotide and Copy Number Variation on Gene Expression Phenotypes
Stranger, B. E., Forrest, M. S., Dunning, M., Ingle, C. E., Beazley, C., Thorne, N., Redon, R., Bird, C. P., de Grassi, A., Lee, C., et al. (2007) · Science · doi:10.1126/science.1136678 · Cited by 1,723
The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution
Farh, K. K.-H., Grimson, A., Jan, C., Lewis, B. P., Johnston, W. K., Lim, L. P., Burge, C. B., & Bartel, D. P. (2005) · Science · doi:10.1126/science.1121158 · Cited by 1,484
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
DNA methylation and the frequency of CpG in animal DNA
Bird, A. P. (1980) · Nucleic Acids Research · doi:10.1093/nar/8.7.1499 · Cited by 1,175
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Self-citationHigashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Hulot, J.-S. (2006) · Blood · doi:10.1182/blood-2006-04-013052 · Cited by 931
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Maternal Methyl Supplements in Mice Affect Epigenetic Variation and DNA Methylation of Offspring
Cooney, C. A., Dave, A. A., & Wolff, G. L. (2002) · The Journal of Nutrition · doi:10.1093/jn/132.8.2393s · Cited by 784
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Effects of DNA methylation on DNA-binding proteins and gene expression
Tate, P. H., & Bird, A. P. (1993) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(93)90027-m · Cited by 737 · cited 1×
“First, DNA methylation of gene promoters may reject the binding of some transcription factors to their DNA binding sites (Tate & Bird, 1993; Rountree et al., 2001).”
BackgroundSIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Self-citationKirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Self-citationPharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother
Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., & Leeder, S. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69255-6 · Cited by 684
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
Self-citationThe genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Hesselink, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00168-1 · Cited by 655
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Self-citationLi, X.-Q., Andersson, T. B., Ahlström, M., & Weidolf, L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.821 · Cited by 644
Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Hulgan, T., Marzolini, C., & Acosta, E. P. (2004) · PubMed · Cited by 627
Molecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
DNA methylation affects the formation of active chromatin
Keshet, I., Lieman-Hurwitz, J., & Cedar, H. (1986) · Cell · doi:10.1016/0092-8674(86)90263-1 · Cited by 588
Hyttel, J. (1982) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(82)80179-6 · Cited by 584
Cytochrome P450 pharmacogenetics and cancer
Rodriguez-Antona, C., & Ingelman-Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 575
Self-citationThe impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., & Cresteil, T. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00625.x · Cited by 539
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Carthew, R. W. (2006) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.02.012 · Cited by 472
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Approaches to microRNA discovery
Berezikov, E., Cuppen, E., & Plasterk, R. H. A. (2006) · Nature Genetics · doi:10.1038/ng1794 · Cited by 458
Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism
Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G., & Thummel, K. E. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.162 · Cited by 449
Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., Malaise, J., Lison, D., Squifflet, J.-P., & Wallemacq, P. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00002 · Cited by 447
Özdemir, V., KALOW, W., Tang, B.-K., Paterson, A. D., Walker, S. E., Endrényi, L., & Kashuba, A. D. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00001 · Cited by 440
Kirchheiner, J., Schmidt, H., Tzvetkov, M., Keulen, J.-T., Lötsch, J., Roots, I., & Brockmöller, J. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500406 · Cited by 439
The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry
Baumann, P., Hiemke, C., Ulrich, S., Eckermann, G., Gaertner, I., Gerlach, M., Kuss, H.-J., Laux, G., Müller-Oerlinghausen, B., Rao, M. L., et al. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832687 · Cited by 419
MicroRNA Regulates the Expression of Human Cytochrome P450 1B1
Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T., & Yokoi, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1403 · Cited by 408
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G., & Fuselli, S. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000239974.69464.f2 · Cited by 398
Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., & Ingelman-Sundberg, M. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20152-5 · Cited by 392
Self-citationAssociation of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
DNA methylation, chromatin inheritance, and cancer
Rountree, M. R., Bachman, K. E., Herman, J. G., & Baylin, S. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204339 · Cited by 384
Developmental Expression of the Major Human Hepatic CYP3A Enzymes
Stevens, J. C., Hines, R. N., Gu, C., Koukouritaki, S. B., Manro, J. R., Tandler, P. J., & Zaya, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054841 · Cited by 368
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348
The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry
Gaertner, I., Baumann, P., Hiemke, C., Ulrich, S., Eckermann, G., Gerlach, M., Kuss, H., Laux, G., Müller-Oerlinghausen, B., Rao, M., et al. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-862645 · Cited by 343
Impact of CYP2D6 genotype on postoperative tramadol analgesia
Stamer, U. M., Lehnen, K., Höthker, F., Bayerer, B., Wolf, S., Hoeft, A., & Stuber, F. (2003) · Pain · doi:10.1016/s0304-3959(03)00212-4 · Cited by 333
CYP3A Variation and the Evolution of Salt-Sensitivity Variants
Thompson, E. E., Kuttab-Boulos, H., Witonsky, D., Yang, L., Roe, B. A., & Di Rienzo, A. (2004) · The American Journal of Human Genetics · doi:10.1086/426406 · Cited by 331
Relevance of DNA methylation in the management of cancer
Esteller, M. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01115-x · Cited by 329
Widschwendter, M., Siegmund, K. D., Müller, H. M., Fiegl, H., Marth, C., Müller-Holzner, E., Jones, P. A., & Laird, P. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3852 · Cited by 324
Macphee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2002) · Transplantation · doi:10.1097/00007890-200212150-00002 · Cited by 315
Bernard, S., Neville, K. A., Nguyen, A. T., & Flockhart, D. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-126 · Cited by 277
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*
Malaiyandi, V., Sellers, E. M., & Tyndale, R. F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.011 · Cited by 267
Vieira, I., Sonnier, M., & Cresteil, T. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0476z.x · Cited by 265
Ghotbi, R., Christensen, M., Roh, H.-K., Ingelman-Sundberg, M., Aklillu, E., & Bertilsson, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0288-2 · Cited by 264
Self-citationHuang, Z., Roy, P., & Waxman, D. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00410-4 · Cited by 263
Floyd, M. D., Gervasini, G., Masica, A. L., Mayo, G., George, A. L., Bhat, K., Kim, R. B., & Wilkinson, G. R. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00003 · Cited by 261
Westlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R., & Ingelman-Sundberg, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.755 · Cited by 258
Self-citationInfluence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A., & Ishizaki, T. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.153 · Cited by 257
Rotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100072 · Cited by 257
Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., Wilkinson, G. R., Clifford, D. B., D’Aquila, R. T., De Gruttola, V., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/497610 · Cited by 257
Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P.-B., Possinger, K., Roots, I., & Brockmöller, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.064 · Cited by 251
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U. M., M??rdter, T. E., Roots, I., & Brockm??ller, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00005 · Cited by 249
Rosen, R. B., & Nishiyama, H. (1965) · PubMed · Cited by 248
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
Shams, M. E. E., Arneth, B., Hiemke, C., Dragicevic, A., Muller, M. J., Kaiser, R., Lackner, K., & Hartter, S. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00763.x · Cited by 246
Fuhr, U., Jetter, A., & Kirchheiner, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100050 · Cited by 245
Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
Ingelman‐Sundberg, M. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00879.x · Cited by 242
Self-citationConcentrations of Tramadol and O-desmethyltramadol Enantiomers in Different CYP2D6 Genotypes
Stamer, U. M., Musshoff, F., Kobilay, M., Madea, B., Hoeft, A., & Stuber, F. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100152 · Cited by 241
Stirzaker, C., Song, J. Z., Davidson, B., & Clark, S. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3690 · Cited by 240
Bahadur, N., Leathart, J. B. S., Mutch, E., Steimel-Crespi, D., Dunn, S. A., Gilissen, R., Houdt, J. V., Hendrickx, J., Mannens, G., Bohets, H., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01354-0 · Cited by 235
Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., & Molden, E. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100291 · Cited by 232
Moclobemide: Therapeutic Use and Clinical Studies
Bonnet, U. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00245.x · Cited by 227
Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene
Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C. J., Burk, O., Buntefuss, D., Escher, S., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200103000-00002 · Cited by 226
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
Bertilsson, L., Dahl, M.-L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., & Ingelman-Sundberg, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92546-6 · Cited by 223
Self-citationShirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K., Takashima, M., Xiao, F., Kosuge, K., Nakagawa, K., Hanai, H., et al. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01108.x · Cited by 221
Ribaudo, H. J., Haas, D. W., Tierney, C., Kim, R. B., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Marzolini, C., Fletcher, C. V., Tashima, K. T., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/499364 · Cited by 221
Obach, R. S., Cox, L. M., & Tremaine, L. M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002428 · Cited by 217
MacPhee, I. A. M., Fredericks, S., Mohamed, M., Moreton, M., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2005) · Transplantation · doi:10.1097/01.tp.0000151766.73249.12 · Cited by 207
Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., & Brockm??ller, J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544120-00002 · Cited by 204
Chang, M., Dahl, M.-L., Tybring, G., Gotharson, E., & Bertilsson, L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00004 · Cited by 203
Cytochrome P 450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer
Tokizane, T., Shiina, H., Igawa, M., Enokida, H., Urakami, S., Kawakami, T., Ogishima, T., Okino, S. T., Li, L.-C., Tanaka, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2545 · Cited by 202
Ferguson, S. S., Chen, Y., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013169 · Cited by 200
Rau, T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.015 · Cited by 197
Marill, J., Cresteil, T., Lanotte, M., & Chabot, G. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12706-x · Cited by 197
Candiotti, K. A., Birnbach, D. J., Lubarsky, D. A., Nhuch, F., Kamat, A., Koch, W. H., Nikoloff, M., Wu, L., & Andrews, D. (2005) · Anesthesiology · doi:10.1097/00000542-200503000-00011 · Cited by 193
Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Okuda, M., Tanaka, K., & Inui, K.-I. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114747.08559.49 · Cited by 189
Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Henningsson, A., Marsh, S., Loos, W. J., Karlsson, M. O., Garsa, A., Mross, K., Mielke, S., Viganò, L., Locatelli, A., Verweij, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1152 · Cited by 188
Pharmacogenomics-based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori
Furuta, T., Shirai, N., Kodaira, M., Sugimoto, M., Nogaki, A., Kuriyama, S., Iwaizumi, M., Yamade, M., Terakawa, I., Ohashi, K., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100043 · Cited by 187
Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine
Burk, O., Tegude, H., Koch, I., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nuessler, A. K., Neuhaus, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202345200 · Cited by 185
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Yasar, Ü., Forslund‐Bergengren, C., Tybring, G., Dorado, P., LLerena, A., Sjöqvist, F., Eliasson, E., & Dahl, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121216 · Cited by 183
GARCIAMARTIN, E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.006 · Cited by 182
Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Messner, B., Kissling, W., & Leucht, S. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.041327 · Cited by 181
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
Niemi, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00228-5 · Cited by 181
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman-Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Self-citationCloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43
Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T. B., Ingelman-Sundberg, M., & Oscarson, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4505 · Cited by 178
Self-citationA COMPARISON OF HEPATIC CYTOCHROME P450 PROTEIN EXPRESSION BETWEEN INFANCY AND POSTINFANCY
Tateishi, T., Nakura, H., Asoh, M., Watanabe, M., Tanaka, M., Kumai, T., Takashima, S., Imaoka, S., Funae, Y., Yabusaki, Y., et al. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)01011-4 · Cited by 174
Parikh, S., Ouedraogo, J.-B., Goldstein, J. A., Rosenthal, P. J., & Kroetz, D. L. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100122 · Cited by 172
The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons
Finta, C., & Zaphiropoulos, P. G. (2000) · Gene · doi:10.1016/s0378-1119(00)00470-4 · Cited by 170
Goetz, M. P., Suman, V. J., Ingle, J. N., Nibbe, A. M., Visscher, D. W., Reynolds, C. A., Lingle, W. L., Erlander, M., Ma, X.-J., Sgroi, D. C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1263 · Cited by 170
Clinical relevance of genetic polymorphisms in the human CYP2C9 gene
Schwarz, U. I. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.6.x · Cited by 170
Lee, S.-J., Usmani, K. A., Chanas, B., Ghanayem, B., Xi, T., Hodgson, E., Mohrenweiser, H. W., & Goldstein, J. A. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00004 · Cited by 167
Nakajima, M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.112688 · Cited by 165
Dahl, M.-L. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping
Frank, D., Jaehde, U., & Fuhr, U. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0250-8 · Cited by 163
Takahashi, H., Kashima, T., Nomoto, S., Iwade, K., Tainaka, H., Shimizu, T., Nomizo, Y., Muramoto, N., Kimura, S., & Echizen, H. (1998) · Pharmacogenetics · doi:10.1097/00008571-199810000-00001 · Cited by 162
Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B., & Li, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015354 · Cited by 160
�gren, H., Bertilsson, L., Kawanishi, C., & Lundgren, S. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0701-4 · Cited by 159
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu, A., Idle, J. R., Byrd, L. G., Krausz, K. W., Kupfer, A., & Gonzalez, F. J. (2003) · PubMed · doi:10.1097/01.fpc.0000054066.98065.7b · Cited by 158
Ferguson, S. S., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.737 · Cited by 158
Tremblay, P., Kaiser, R., Sezer, O., Rösler, N., Schelenz, C., Possinger, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.164 · Cited by 157
DNA methylation and chromatin structure: The puzzling CpG islands
Caiafa, P., & Zampieri, M. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20325 · Cited by 155
Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127637 · Cited by 153
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-rime PCR
Schaeffeler, E., Schwab, M. G., Eichelbaum, M. F., & Zanger, U. M. (2003) · Human Mutation · doi:10.1002/humu.10280 · Cited by 153
Wilson, R. C., Nimkarn, S., Dumić, M., Obeid, J. S., Azar, M. R., Najmabadi, H., Saffari, F., & New, M. I. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.12.005 · Cited by 152
Functional Characterization of Cytochrome P450 2B6 Allelic Variants
Jinno, H., Tanaka‐Kagawa, T., Ohno, A., Makino, Y., Matsushima, E., Hanioka, N., & Ando, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.398 · Cited by 152
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
CYP2A6 genetic variation and potential consequences
Xu, C. D., Goodz, S. D., Sellers, E. M., & Tyndale, R. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00065-0 · Cited by 147
Murray, M. T. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.7.0001 · Cited by 139
Perry, P. J., ZEILMANN, C., & Arndt, S. V. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199408000-00002 · Cited by 137
Variability of CYP3A7 expression in human fetal liver
Leeder, J. S., Gaedigk, R., Marcucci, K. A., Gaedigk, A., Vyhlidal, C. A., Schindel, B. P., & Pearce, R. E. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086504 · Cited by 136
Umeno, M., Song, B. J., Kozak, C. A., Gelboin, H. V., & Gonzalez, F. J. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68880-5 · Cited by 134
The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals
Hodgson, E., & Rose, R. L. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.10.002 · Cited by 134
Edwards, R. J., Adams, D. A., Watts, P. S., Davies, D. S., & Boobis, A. R. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00033-1 · Cited by 134
Klotz, U. E. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44297 · Cited by 132
Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro
Kobayashi, K., Ishizuka, T., Shimada, N., Yoshimura, Y., Kamijima, K., & Chiba, K. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15222-1 · Cited by 127
Enggaard, T. P., Poulsen, L. K., Arendt‐Nielsen, L., Brøsen, K., Ossig, J., & Sindrup, S. H. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000189613.61910.32 · Cited by 126
Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study
Fux, R., Mörike, K., Pröhmer, A. M. T., Delabar, U., Schwab, M. G., Schaeffeler, E., LORENZ, G., Gleiter, C. H., Eichelbaum, M. F., & Kivistö, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.004 · Cited by 126
Daigo, S., Takahashi, Y., Fujieda, M., Ariyoshi, N., Yamazaki, H., Koizumi, W., Tanabe, S., Saigenji, K., Nagayama, S., Ikeda, K., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00005 · Cited by 125
Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking.
Anttila, S. L., Hakkola, J., Tuominen, P., Elovaara, E., Husgafvel‐Pursiainen, K., Karjalainen, A., Hirvonen, A., & Nurminen, T. (2003) · PubMed · Cited by 118
Human SULT1A1 gene: copy number differences and functional implications
Hebbring, S. J., Adjei, A. A., Baer, J. L., Jenkins, G. D., Zhang, J., Cunningham, J. M., Schaid, D. J., Weinshilboum, R. M., & Thibodeau, S. N. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl468 · Cited by 117
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction
Yasar, ?., Bennet, A. M., Eliasson, E., Lundgren, S., Wiman, B., Fairé, U. D., & Rane, A. (2003) · Pharmacogenetics · doi:10.1097/00008571-200312000-00002 · Cited by 116
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
Karlgren, M., Gomez, A. V., Stark, K., Svärd, J., Rodríguez‐Antona, C., Oliw, E. H., Bernal, M. L., y Cajal, S. R., Johansson, I., & Ingelman‐Sundberg, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.200 · Cited by 115
Self-citationScreening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
Yu, A., Idle, J. R., Herraiz, T., Kupfer, A., & Gonzalez, F. J. (2003) · PubMed · doi:10.1097/01.fpc.0000054094.48725.b7 · Cited by 111
Rodríguez‐Antona, C., Sayi, J., Gustafsson, L. L., Bertilsson, L., & Ingelman‐Sundberg, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.020 · Cited by 111
Self-citationHo, K., & Gan, T. J. (2006) · Current Opinion in Anaesthesiology · doi:10.1097/01.aco.0000247340.61815.38 · Cited by 110
Tada, H., Tsuchiya, N., Satoh, S., Kagaya, H., Li, Z., Sato, K., Miura, M., Suzuki, T., Kato, T., & Habuchi, T. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.02.073 · Cited by 110
Sim, S. C., Edwards, R. J., Boobis, A. R., & Ingelman‐Sundberg, M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000171516.84139.89 · Cited by 107
Self-citationEffect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients
Kurzawski, M., Gawronska-Szklarz, B., Wrześniewska, J., Siuda, A., Starzyñska, T., & Droździk, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0183-2 · Cited by 106
Padol, S., Yuan, Y., Thabane, M. E., Padol, I. T., & Hunt, R. H. (2007) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp45188 · Cited by 105
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
Kawamura, M., Ohara, S., Koike, T., Iijima, K., Suzuki, J., Kayaba, S., Noguchi, K., Hamada, S., Noguchi, M., & Shimosegawa, T. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01539.x · Cited by 102
Schwab, M. G., Schaeffeler, E., Klotz, U. E., & Treiber, G. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.002 · Cited by 97
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
Herrlin, K., Yasui‐Furukori, N., Tybring, G., Widén, J., Gustafsson, L. L., & Bertilsson, L. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01874.x · Cited by 96
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype
Jiang, Z., Dragin, N., Jorge-Nebert, L. F., Martin, M. V., Guengerich, F. P., Aklillu, E., Ingelman‐Sundberg, M., Hammons, G., Lyn‐Cook, B. D., Kadlubar, F. F., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000204994.99429.46 · Cited by 93
Self-citationInducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2
Han, X., Ouyang, D., Chen, X., Shu, Y., Jiang, C., Tan, Z., & Zhou, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01686.x · Cited by 92
Therapeutic Drug Monitoring of Antidepressants
Burke, M. J., & Preskorn, S. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937020-00004 · Cited by 91
Treatment concepts of acute promyelocytic leukemia
Lengfelder, E., Saußele, S., Weisser, A., Büchner, T., & Hehlmann, R. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.009 · Cited by 90
PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19
Yu, B., Chen, G., He, N., Ouyang, D., Chen, X., Liu, Z., & Zhou, H. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1255 · Cited by 88
Yu, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114231 · Cited by 87
CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia
Inomata, S., NAGASHIMA, A., Itagaki, F., Homma, M., Nishimura, M., Osaka, Y., OKUYAMA, K., Tanaka, E., Nakamura, T. K., & Kohda, Y. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.020 · Cited by 86
Mirghani, R. A., Sayi, J., Aklillu, E., Allqvist, A., Jande, M. B., Wennerholm, A., Eriksen, J., Herben, V. M. M., Jones, B., Gustafsson, L. L., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230411.89973.1b · Cited by 85
Epigenetic Inactivation of the Dioxin-Responsive Cytochrome P4501A1 Gene in Human Prostate Cancer
Okino, S. T., Pookot, D., Li, L., Zhao, H. L., Urakami, S., Shiina, H., Igawa, M., & Dahiya, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0504 · Cited by 84
Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
Sindrup, S. H., Poulsen, L. K., Brøsen, K., Arendt‐Nielsen, L., & Gram, L. F. (1993) · Pain · doi:10.1016/0304-3959(93)90229-i · Cited by 83
Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids
Marill, J., Capron, C., Idres, N., & Chabot, G. G. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00925-x · Cited by 81
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam
Kosaki, K., Tamura, K., Sato, R., Samejima, H., Tanigawara, Y., & Takahashi, T. (2004) · Brain and Development · doi:10.1016/j.braindev.2004.02.010 · Cited by 80
Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L. L., & Ingelman‐Sundberg, M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00005 · Cited by 78
Self-citationMwenifumbo, J. C., Lessov-Schlaggar, C. N., Zhou, Q., Krasnow, R. E., Swan, G. E., Benowitz, N. L., & Tyndale, R. F. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100246 · Cited by 76
Take, S., Mizuno, M., Ishiki, K., Nagahara, Y., Yoshida, T., Inaba, T., Yamamoto, K., Okada, H., Yokota, K., Oguma, K., et al. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00713-5 · Cited by 76
Metabolic Ratios of Psychotropics as Indication of Cytochrome P450 2D6/2C19 Genotype
van der Weide, J., van Baalen-Benedek, E. H., & Kootstra‐Ros, J. E. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000162868.84596.c3 · Cited by 75
Expression of CYP2W1 in colon tumors: Regulation by Gene Methylation
Gomez, A. V., Karlgren, M., Edler, D., Bernal, M. L., Mkrtchian, S., & Ingelman‐Sundberg, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.10.1315 · Cited by 72
Self-citationDetermination of CYP2D6 Gene Copy Number by Pyrosequencing
Söderbäck, E., Zackrisson, A., Lindblom, B., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.043182 · Cited by 71
Rodríguez‐Antona, C., Niemi, M., Backman, J. T., Kajosaari, L. I., Neuvonen, P. J., Robledo, M., & Ingelman‐Sundberg, M. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500482 · Cited by 70
Self-citationXu, Z., Wang, W., Zhao, X., Huang, S., Zhu, B. Y., He, N., Shu, Y., Liu, Z., & Zhou, H. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00023.x · Cited by 69
Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles
Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman‐Sundberg, M., Härtung, T., & Coecke, S. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.04.001 · Cited by 67
Self-citationde León, J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318058244d · Cited by 65
Amiodarone N‐Deethylation by CYP2C8 and its Variants, CYP2C8*3 and CYP2C8 P404A
Soyama, A., Hanioka, N., Saito, Y., Murayama, N., Ando, M., Ozawa, S., & Sawada, J. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.910404.x · Cited by 64
Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies
Hildebrandt, M. A. T., Salavaggione, O. E., Martin, Y. N., Flynn, H. C., Jalal, S. M., Wieben, E. D., & Weinshilboum, R. M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.038 · Cited by 63
Jones, S., Boobis, A. R., Moore, G. E., & Stanier, P. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90726-y · Cited by 63
CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir
Josephson, F., Allqvist, A., Janabi, M., Sayi, J., Aklillu, E., Jande, M. B., Mahindi, M., Burhenne, J., Böttiger, Y., Gustafsson, L. L., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100117 · Cited by 63
Rodríguez‐Antona, C., Jande, M. B., Rane, A., & Ingelman‐Sundberg, M. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.003 · Cited by 63
Self-citationShimoda, K., Someya, T., Yokono, A., Morita, S., Hirokane, G., Takahashi, S., & Okawa, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00007 · Cited by 61
Schweizer, E. E., Rynn, M. A., Mandos, L. A., DeMartinis, N. A., a, F. G. A.-E., & Rickels, K. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200105000-00002 · Cited by 61
Smit, P., van Schaik, R. H. N., van der Werf, M., van den Beld, A. W., Koper, J. W., Lindemans, J. W., Pols, H. A. P., Brinkmann, A. O., de Jong, F. H., & Lamberts, S. W. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0307 · Cited by 61
Ishikawa, C., Ozaki, H., Nakajima, T., Ishii, T., Kanai, S., ANJO, S., Shirai, K., & Inoue, I. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0188-6 · Cited by 60
Association between cytochrome P450 2D6 genotype and harm avoidance
Roberts, R. L., Luty, S. E., Mulder, R., Joyce, P. R., & Kennedy, M. A. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20163 · Cited by 60
Tissue-specific expression and methylation of the human CYP2E1 gene
Botto, F., Sérée, E., Khyari, S. E., de Sousa, G., Massacrier, A., Placidi, M., Cau, P., Pellet, W., Rahmani, R., & Barra, Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90145-7 · Cited by 59
Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status
Hirota, T., Ieiri, I., Takane, H., Maegawa, S., Hosokawa, M., Kobayashi, K., Chiba, K., Nanba, E., Oshimura, M., Satō, T., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh313 · Cited by 58
THE IMPACT OF CYP2C9 GENETICS AND ORAL CONTRACEPTIVES ON CYTOCHROME P450 2C9 PHENOTYPE
Sandberg, M., Johansson, I., Christensen, M., Rane, A., & Eliasson, E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.484 · Cited by 57
Rudberg, I., Hendset, M., Uthus, L. H., Molden, E., & Refsum, H. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000189899.23931.76 · Cited by 56
Evidence of Polymorphic CYP2C19 Involvement in the Human Metabolism of N-Desmethylclobazam
Contin, M., Sangiorgi, S., Riva, R., Parmeggiani, A., Albani, F., & Baruzzi, A. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200212000-00009 · Cited by 54
Cited by
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
The Sympathetic Nervous System in Heart Failure
Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., & Butler, J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.015 · Cited by 978
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes
Waxman, D. J., & Holloway, M. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056705 · Cited by 815
Metadata
- Authors
- Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 116
- Issue
- 3
- Pages
- 496-526
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2121074897
- Cited by
- 1,166
- References
- 221
- FWCI
- 67.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.